Maximal lipid lowering therapy decreases calcified plaque volume and increases calcified plaque density  by Hoffmann, Udo et al.
JACC March 6, 2002 
values distributed between 2.0 and 2.9 with the different devices. The 95% confidence 
limits around any given INR were calculated and are presented in the table. 
Conclusion: There is significant device dependent variation in INR determinations with 
different POC testing technologies that is large enough to have significant clinical impact. 
95% Confidence Limits Across Different Test Systems 
Upper Limit 1.7 2.3 2.9 3.6 4.8 
INR 1.5 2.0 2.5 3.0 4.0 
Lower Limit 1.2 1.6 2.0 2.3 3.1 
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1107-85 Simvastatin Reduces Bone Turnover in 
Hyperchoiesterolemic Subjects Independent of Its 
Effects on LDL Oxidation and Inflammatory Markers 
Robert S. Rosenson, Craig B. Langman, Christine C. Tangney, Ellen R. Brooks, Thomas 
Parker, Daniel Levine, Bruce Gordon, Northwestern University Medical School, Chicago, 
Illinois, The Rogosin Institute, New York, New York. 
Objective: Inflammation has been recognized as a common mechanism underlying 
pathologic bone resorption and vascular calcification. Retrospective studies indicate that 
statins reduce bone fracture and coronary calcification. We investigated the effects of 
short-term (average of 7 and 8 weeks) statin therapy on (1) serum bone markers (bone 
specific alkaline phosphatase [BAP], osteocalcin [OC], and type I collagen N-telopeptide 
cresslinks [NTX]), and (2) their relationships to changes in oxidized LDL and selected 
inflammatory markers (soluble tumor necrosis factor receptors 1 and 2 [TNF R1 and R2], 
high-sensitivity CRP [hs-CRP]. 
Methods: 63 (M/F 40/23) healthy nonsmoking adults (mean ± SD, aged 51.0±8.0 y; BMh 
28.5±5,3 kg/m 2) with LDL-C between 130-189 mg/dL were randomized and treated for 8 
weeks with placebo (n=17), pravastatin 40 mg/d (n=15), simvastatin 20 mg/d (n=14) or 
simvastatin 60 mg/d (n=l 7). Fasting blood samples were acquired twice at baseline, and 
twice at study completion. 
Results: Statin therapy reduced serum BAP (group by time interaction, p= 0.004). Spe- 
cifically, simvastatin 60 mg reduced BAP (-2.3 U/L, p=0.04), whereas no change was 
seen with simvastatin 20 mg (-0.08 U/L, p =0,71), pravastatin (+0.51 U/L, p=0.21) or pla- 
cebo (0.37 U/L, p=0.51). Change in BAP (by one-way ANOVA with Student-Neuman 
Keuls test) in the simvastatin 80 mg group was different from the other treatment groups 
(p<0.05). The changes in BAP remained significant after adjustment for age, gender, and 
BMI. No significant differences were seen in OC or NTX. Reductions in LDL-C correlated 
with reductions in BAP (rho=0.25, p=0.05) across treatment groups. Statin therapy 
reduced LDL oxidative susceptibility (p = 0,014); however sTNF R1 and R2 and hs-CRP 
were unchanged. Reduction in BAP was not correlated with changes in oxidized LDL, or 
selected inflammatory markers. 
Conclusions: Short-term use of high-dose simvastatin lowers the Level of the serum 
bone marker BAP, suggestive of reduced bone turnover. The beneficial effects of high- 
dose simvastatin were unrelated to changes in LDL oxidation or certain inflammatory 
pathways. 
1107-86 In Vivo Effects of Atorvastatin on Bone Metabolism Is 
Vitamin D-Dependent 
Kou!i Kaiinami. Noboru Takekoshi, Shinobu Matsui, Hiroichi Tsugawa, Seiyu Kanemitsu, 
Bhinji Okubo, Kanazawa Medical Universi~ Uchinada-machi, Japan. 
Background: Some studies reported the significant association between statin therapy 
and reduced risk of fracture or increased bone mineral density. However, others failed to 
find this association, and clinical evidence potentially related to its mechanism has not 
been reported. 
Methods: To find the clinical variables to predict the effects of statin therapy on bone 
metabolism, we enrolled 34 patients (mean age 52 years) with heterozygous familial 
hypercholesterolemia in prospective 24-week treatment with 40 rag/day of atorvastatin. 
Serum levels of bone specific alkaline phosphatase (BALP) and osteocalcin (OC) were 
determined as bone formation marker, and urine collagen type 1 crosslinked N-telopep- 
tide (NTx) levels as bone resorption marker, in addition to serum levels of parathyroid 
hormone and 1.25(OH)2 vitamin D3 (VitD). 
Results: After discontinuation of any lipid-modifying therapy for more than 4 weeks, ator- 
vastatin 40 mg/day treatment produced 40% (345 to 208 mg/dl) and 49% (267 to 136 rag/ 
dl) reduction in total and LDL cholesterol levels, and 10% increase (51 to 56 mg/dl) in 
HDL cholesterol level, respectively. As a whole study group, none of examined markers 
showed significant alterations during treatment. However, in 14 subjects with higher VitD 
levels (>50 pg/mL) before treatment, significant increase of BALP (22.4 to 26.6 U/L) and 
small decrease of NTx (37.6 to 35.0 nMCBE/ml) were observed, whereas remaining 20 
subjects with lower VitD levels did not. PTH levels did not produce significant effects on 
alterations of markers during treatment. 
Conclusion: In vivo effects of atorvastatin on bone metabolism appears to be vitamin D- 
dependent. 
1107-87 Maximal Lipid Lowering Therapy Decreases Calcified 
Plaque Volume and Increases Calcified Plaque Density 
Udo Hoffmann, Kurt Dertler, Martin Haas, Alfred Stadler, Thomas J. Brady, Karam 
Kostner, General Hospital and University of Vienna, Vienna, Austria, Massachusetts 
General Hospital and Harvard Medical School, Boston, Massachusetts. 
Background: Coronary artery calcification is closely related to the history of elevated 
blood lipoprotein levels. We investigated the long term effect of maximal lipid lowering in- 
tervention on calcified coronary plaque characteristics in patients with familial hypercho- 
lesterolemia (FH) using computed tomography (CT). 
Methods: Heterozygote FH patients (n=8, mean age: 46_+7.6 years) were studied over a 
time period of 29 months. Patients underwent regularly LDL- apheresis (n=101_+21) and 
received Atorvastatin (80mg/daily). Blood lipopretein levels were measured at baseline 
1106-83 Antiplatelet Effects of Angiotensin Converting Enzyme 
Inhibitora Compared with Aspirin and Clopidogrel: A 
Pilot Study Using Whole Blood Aggregometry 
Dirk Skowasch, Melanie Schneider, Ren~ Andri~, Berndt L~dedtz, Gerhard Bauriedel. 
Department of Cardiology, University of Bonn, Bonn, Germany, 
Background: Platelet activation and subsequent aggregation play a key role in complica- 
tions and progression of atherosclerosis. While specific antiptatelet agents work as well- 
established, effective components in secondary prevention, recent clinical trials showed 
a decrease in cardiovascular events also for angiotensin converting enzyme (ACE) inhib- 
itors. Therefore, in the present study, we sought to assess the coagulative activity of car- 
diovascular patients grouped for treatment with either ACE inhibitors, aspirin, clopidogrel/ 
aspirin or none of these medications. 
Methods: Blood samples from 223 cardiovascular patients were analyzed by whole- 
blood aggregometry. Platelet aggregation was determined by the increase in impedance 
across paired electrodes in response to the aggregatory agents ADP and collagen, resp. 
These data were regarded for presence/absence of ACE inhibition or antithrombotic 
medication. 
Results: The central finding was that platelet aggregation was attenuated by ACE inhibi- 
tors as well as by either aspirin or clopidogrel/aspirin, indicated by a lower impedance 
increase compared to no medication. With ACE inhibition, platelet aggregation 
decreased by 36% (p=0.04) following ADP induction. No significant antithrombotic effect 
was seen with aspirin alone (34%; p=0.10), while decrease in ADP induced platelet 
aggregation was extensive with clopidogrel/aspirin (90%; p=0.001 ). After collagen induc- 
tion, there was a trend to reduced platelet aggregation with ACE inhibitor therapy (14%; 
p=0.20), whereas inhibition with aspirin was 20% (p=0.02) and that with clopidogrel/aspi- 
rin 31% (p=0.04) compared to untreated participants. 
Conclusions: These ex vivo data on whole-blood aggrogomatry provide direct evidence 
for ACE inhibitors to decrease platelet aggregation, while confirming aspirin and clopi- 
dogrel as established antithrombotics. Antiaggregatory effects with ACE inhibition may 
contribute to the beneficial influence of this drug class on major clinical, cardiovascular 
endpoints and offer an important herapeutic option in case of aspirin/clopidogrel intoler- 
ance. 
1106-84 The Effect of Drugs Which Are Known Inducers and 
Inhibitors of Human Cytochrome P450 3A on the 
Platelet Inhibitory Activity of Clopidogrel 
Wei C. Lau. Lucy Waskell, Paul B. Watkins, Charlene Neer, David Carville, Kirk E. Guyer, 
Kevin Horowitz, Eric R. Bates, University of Michigan Health System, Ann Arbor, 
Michigan, Indiana University, South Bend, Indiana. 
Background: Clopidogrel is a prodrug, which is converted to an active drug in the liver by 
cytochreme P450 (CYP). The metabolite forms a disulfide bond with the platelet ADP 
receptor, P2cyc. Platelets with a modified receptor are defective in their ability to aggre- 
gate. Two studies were undertaken to determine whether the most abundant human 
CYP, 3A4 activates clopidogrel. 
Methods: Study 1. Twenty volunteers had platelet aggregation measured with ADP ago- 
nist (Plateletworks TM) at baseline and after 6 days of clopidogrel (75 mg). After a 2 week 
washout period, erythromycin (250 mg qid), a CYP3A4 inhibitor, and rifampin (300 mg 
bid), a CYP3A4 inducer, were each given to 10 volunteers concomitant with ctopidogrel. 
Platelet aggregation was measured at baseline and 6 days. Study 2. Clopidogrel (450 
mg) was given to 5 volunteers and platelet aggregation was measured at baseline and 4 
hours. Two weeks later, troleandomycin (500 mg), the most potent CYP3A4 inhibitor, and 
clopidogret (450 mg) were both given. Platelet aggregation measurements were 
repeated at baseline and at 4 hours 
Results: Study 1. Erythromycin increased platelet aggregation form 48% to 59% 
(p=0.005). Rifampin decreased platelet aggregation from 55% to 33% (p=0.001). Study 
2. Clopidogrel initially reduced platelet aggregation from 93% to 50% (p=0.02). An eryth- 
romycin breath test showed that the addition of troleandomycin completely inhibited 
CYP3A4 activity: platelet aggregation was reduced from 90% to 80% (p=NS). 
Conclusion: These data are consistent with the hypothesis that CYP3A4 in humans 
mediates the conversion of clopidogrel to an active drug. Therefore, clopidogrel will be 
susceptible to drug interactions with the numerous medications that are inducers or 
inhibitors of CYP3A4. 
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and pra and post each apheresis session using routine laboratory assays. Features of 
calcified coronary plaque burden (Agatston Score, calcified plaque vol-ume, calcified 
plaque density) were measured using ECG- triggered fast CT at baseline and at the end 
of the study period. The effects of decreased blood lipoprotein exposure on coronary cal- 
cified plaque were evaluated. On average, total cholesterol, LDL- cholesterol, triglycer- 
ides and Lipoprotein (a) were substantially lowered as compared to baseline (52.9%, 
P<0.0G01 ; 64.5%, P<0.O001; 48.7%, P<0.004 and; 45.3%, P<0.05), respectively. In con- 
trast, mean HDL Cholesterol increased by 13.9% (P<0.07). Concomitantly the Agat-ston 
Score decreased by 26.1+14.3% (213.'~?.03, P<0.03), calcified plaque volume was 
reduced by 23.4±14.8% (186±199 ram3, P<0.03) and calcified plaque density increased 
by 17.2_+10.7% (40~32 HU, P<0.01). The increase of plaque density was correlated to 
the reduction of total cholesterol levels (r=0.73, P<0.04). 
Conclusion: Coronary calcified plaque volume decreases and mean calcified plaque den- 
sity increases during long term maximal lipid lowering intervention. This regression 
potentially depends on the extent of lipid lowering and can be tracked quantitatively by 
computed tomography. 
1107-88 Statin Therapy but Not Exercise Inhibits Rates of  
Progression of Coronary Calc i f icat ion 
Matthew J. Budoff, Nisha Agrawal, David S. Reiss, Tej Naik, Thuy Le, Kedisha Mayet, 
Harbor-UCLA Research and Education Institute, Torrance, California. 
Background: Coronary artery calcification (CAC) by Electron Beam Tornography (EBT) is 
linearly associated with atherosclerotic plaque burden. The influence of different thera- 
pies to influence EBT calcium progression has not been well described. 
Methods: The aim of this study was to determine the changes in CAC, under the influ- 
ence of several interventions, as measured by electron beam tomography in consecutive 
patients presenting in our laboratory for follow-up. To evaluate the rates of progression, 
we evaluated 555 patients (mean age 59 +/-9 years, 78% men). The interscan period 
was 3.0 +/- 1.6 years. EBT scores were calculated using the Agatston method. The 
results were reported in % EBT score change/year. Due to high variabilities in the very 
low scores, patients with baseline scores >10 were included. Multivariate analysis was 
used to assess the independent effects of different therapies or conditions. 
Results: Mean calcium score in this cohort was 257, and increased by 29.5 points per 
year. The mean rate of progression of the entire cohort was 18+/-7%. 241 patients were 
treated with statin therapy during the entire interscan period, with mean progression of 
13+/-11%. In the 89 patients with high cholesterol who were not taking therapy, the rate 
of progression was 29+/-12% per year. There was a significant difference between the 
rates of progression between the groups (p=0.005). This study demonstrated statin ther- 
apy to be a significant, independent predictor of the progression of coronary calcium 
(odds ratio [OR] 2.41; 95% confidence interval [CI], 1.29, 4.75). Patients reporting regular 
exercise (n=334) had a rate of progression of 16+/-8%, while persons reporting no exer- 
cise had progression rates of 19+/-9% per year (p=n.s.). No cardiovascular risk factors 
were related to progression of plaque in the multivariate model. 
Conclusion: Statin therapy, but not exercise, inhibited CAC progression. The prognostic 
significance of increasing CAC plaque remains to be determined. However, given the 
association of increased atherosclerosis with increased CAC, use of cholesterol-lowering 
therapy should be considered in patients with CAC to slow plaque progression. 
1107-89 Change in Calci f ied Plaque Burden in Relation to  
Aggressiveness of Treatment and Baseline LDL 
Cholesterol Levels 
Harvev S. Hecht, S Mitchell Harman, Heart and Vascular Institute, Mordstown, New 
Jersey, Kronos Research Institute, Phoenix, Arizona. 
To determine 1) whether or not progression of calcified plaque burden in the primary pre- 
vention population is significantly reduced by more aggressive LDLC lowering and 2) 
whether treatment will benefit pts with NCEP higher risk initial LDLC more than lower risk 
pts, 172 asymptomatic men (137) and women (35) without clinical CAD were evaluated 
by serial Electron Beam Tomography (EBT), before and 1.2±0.3 yrs after intitiation of 
lipid therapy. Statins were used in 163, niacin in 98, fibrates in 2, and statin+niacin in 85. 
Percent change/yr in EBT volume (V) and score (S) were compared in pts achieving final 
(F) LDLC80mg/dl and in pts with initial (I) LDLC >130 vs <130 mg/dl (Table). Conclu- 
sions: 1)After 1.2 yrs of treatment, there were no differences in calcified plaque burden 
progression in pts achieving LDLCS0 mg/dl; i.e. lower was not better, and plaque pro- 
gression was similar with initial LDLC<130 vs >130mg/dl; i.e. in pts defined as lower vs 
higher risk by NCEP. 2) A longer treatment period may be needed to produce differences 
between groups. 
Changes In EBT Calcium In Relation to Rlek (Initial LDLC) and Response to 
Treatment (Final LDLC) 
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Final LDL F >80 F*80 pvalue Initial LDL 1>130 1"130 p value 
n 74 98 n 82 87 
I-LDLC 138±46 122±28 0.007 LDLC 156±31 104±21 <0.001 
I-EBT S 380±390 513±698 0.07 I-EBT S 453±501 592±829 0.16 
F-LDLC 99±18 64±11 <0.001 F-LDLC 85±23 73±19 <0.001 
I-EBT V 307±315 407±544 0.08 I-EBT V 353±381 468±646 0.17 
%changeS/yr 19.5±45.3 12.2±29.8 0.20 %changeS/yr 12.8±23.2 16.6±46.6 0.52 
%change V/yr 15.1±35.8 12.3±28.1 0.57 %changeV/yr 11.8±24.0 14.5±36.8 0.57 
1107-90 Comparison of Statin Versus Ststin+Niacin Treatment in 
Primary Prevention: Effect on Change in Calcified 
Plaque Burden 
Harvev S. Hecht. S Mitchell Harman, Heart and Vascular Institute, Morristown, New 
Jersey, Kronos Research Institute, Phoenix, Arizona. 
The effects on calcified plaque burden by Electron Beam Tomography (EBT) of statin 
therapy (ST) to lower LDLC and stalin+niacin therapy (ST+N) to treat combined LDLC 
and HDLC/Trig abnormalities were compared in 162 asymptomatic patients without clini- 
cal CAD. EBT score (S) and volume (V) were obtained before and after a mean of 1.25 
yrs of ST (n=78) or 1.18 yrs of ST+N (n=84) therapy. Except for HDLC in the S group, 
lipid and EBT values all changed significantly after treatment (Table), Final LDLC was 
lower in the ST+N group (p<.03) but final HDLC and Trig did not differ significantly. There 
were no significant differences between groups in the change in LDLC, but changes in 
HDLC (p<0.0001) and Trig (p<0.006) were greater in the ST+N group. There were no dif- 
ferences between ST and ST+N in % change in EBT-S/yr (13.4 vs 17.2, p=0.9) or % 
change in EBT-V/yr (11.2 vs 16.4, p=0.77). Conclusions: ST and ST+N therapies 1) 
addressed different lipid profiles and produced significantly improved lipid values, and 2) 
did not differ in terms of rates of calcified plaque progression after t .2 yrs of treatment. 
Changes In Lipid and EBT Values In Patients on Statln end Statln + Niacin 
Statin Stalin + Niacin 
Baseline Final p value Baseline Final p value 
LDLC 134±41 83±23 <0.001 129±30 73±18 <0.001 
HDLC 58±17 60±18 0.21 44±12 54±14 <0.001 
Trig 119±71 95±57 <0.001 170±121 109±63 <0.001 
EBT-S 449±698 507±825 0.004 484±486 552+563 <0.0001 
EBT-V 359±564 399±638 0.01 387±383 434±424 <0.001 
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1108-69 Regression of Echocardiographic Left Ventricular 
Hypertrophy in Relation to Resolution Versus 
Persistence of Electrocardiographic Strain After One 
Year of Antlhypertensive Therapy: The LIFE Study 
Peter M. Okin, Richard B. Devereux, Vittorio Palmieri, Jennifer E. Liu, Kristian Wachtell, 
Markku S. Nieminen, Sverker Jam, Lasse Oikarinen, Matti Viitasalo, Sverre E. Kjeldsen, 
Stevo Julius, Bjorn Dahlof, for the LIFE Study Investigators, Cornel/Medics~ Center, New 
York, New York. 
Background: Presence of the ECG strain pattern (ST depression and T-wave inversion 
in leads V5 and/or V6) at LIFE study baseline was associated with greater left ventricular 
mass index (LVMI) and a higher prevalence of LV hypertrophy (LVH). However, the rela- 
tion of resolution vs persistence of ECG strain to changes in LVM and LVH over time is 
uncertain. Methods: 597 patients (pts) with ECG LVH by either Cornell product and/or 
Sokolow-Lyon voltage, enrolled in the LIFE echocardiographic substudy, were examined 
at study baseline and after 1-year of blinded therapy with either Iosartan or atenolol 
based regimens. Echocardiographic LVH was defined by LVMt >116 g/m 2 in men and 
>104 in women. Results: ECG strain was absent at baseline and 1-year (S-/-) in 511 pts, 
present on both ECGs (S+/+) in 47 pts, and was present at baseline but had resolved by 
1-year (S+/-) in 39 pts. At study baseline, compared with S-/- pts, S+/+ and S+/- pts had 
similarly high prevalences of LVH, but the LVH was more severe, with greater LVMI, in 
S+/+ than S+/- pts (p=.038); S-/- pts had significantly lower LVMI and prevalence of LVH. 
After 1-year, S+/+ pts had the greatest LVMI and prevalence of LVH, whereas S+/- pts 
had lower LVMI and prevalence of LVH. (*p<.001 vs baseline) 
Variable Strain-/- Strain+/- Strain+/+ p value 
(n=511) (n=39) (n=47) 
LVMI at baseline (g/m 2) 120±.23 136+25 148+38 <.001 
LVMI at 1 -year (g/m 2) 107_+20* 115¢25" 133_+31 * <.001 
LVH at baseline (%) 66 90 87 <.001 
LVH at 1-year (%) 39* 54* 75 <.001 
Conclusions: In the setting of aggressive antihypertensive therapy and decrease in 
blood pressure, persistence of ECG strain identifies a subgroup of pts with greater l-year 
LVMI and LVH. In contrast, resolution of strain was associated with a marked reduction in 
the risk of LVH at t-year. 
